Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FAMOS

Financiado

Cerrado

Functional anatomical molecular optical screening

Biophotonics offers low-cost, non-invasive, accurate, rapid alternatives to conventional diagnostic methods and has the potential to address medical needs with early detection and to reduce the cost of healthcare. FAMOS will devel... ver más

31/03/2017

MEDIZINISCHE UNIVE...

13M€

Presupuesto del proyecto: 13M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-03-31 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

MEDIZINISCHE UNIVERSITAET WI...

0.00€ | Lider

ITHERA MEDICAL GMBH

N.D. | Participante

UNIVERSITY COLLEGE LONDON

Proyectos interesantes

PHAST

Medical Technol...

Applied Physics

4M€ Cerrado

LiPhos

Medical Technol...

Applied Physics

4M€ Cerrado

PDC2023-145869-I00

Medical Technol...

Applied Physics

290K€ Cerrado

FBI

Medical Technol...

Applied Physics

4M€ Cerrado

CNS2023-145366

Medical Technol...

Applied Physics

199K€ Cerrado

DPI2014-56850-R

Medical Technol...

Applied Physics

182K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 13M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Biophotonics offers low-cost, non-invasive, accurate, rapid alternatives to conventional diagnostic methods and has the potential to address medical needs with early detection and to reduce the cost of healthcare. FAMOS will develop a new generation of light sources with step-changes in performance beyond the state-of-the-art to radically transform biophotonic technologies for point-of-care diagnosis and functional imaging. This will enable optical diagnostics with superior sensi-tivity, specificity, reliability and clinical utility at reduced cost, heralding an imaging renaissance in Europe.FAMOS addresses optical imaging from molecular over (sub)cellular to individual organs, with no gap in the arsenal of diagnostic tools for medical end-users. The world-class multidisciplinary FA-MOS team of 7 leading academic institutions and 10 top SMEs has unique complementary knowledge of optical coherence tomography, adaptive optics, photoacoustic tomography, coherent anti-stokes Raman scattering, multiphoton tomography as well as swept-source, diode-pumped ultrafast and tuneable nanosecond pulse lasers. Combinations of some techniques will offer multi-modal solutions to diagnostic needs that will exploit and enhance the benefits of each modality. FAMOS technologies have wide applicability, but our specific focus is on diagnosis in ophthalmol-ogy and oncology. Partnerships with leading innovative clinical users will enable preclinical evalua-tion.The objectives of FAMOS are:\tDevelop new light sources with a step-change in performance (2-3 times more compact and up to 3-4 times cheaper diode pumped Ti:sapphire, 4-10 times faster swept sources and tuneable nanosecond pulse sources)\tIntegrate these with optical imaging for a step-change in diagnosis (2-5 times better resolution cellular retinal imaging with more than 10 times larger field of view, up to 10 times enhanced penetration single source subcellular morphologic imaging, increased selectivity of intrinsic mo-lecular sensing as well as several frames per second deep tissue functional tomography\tPerform preclinical studies to demonstrate novel or improved ophthalmic and skin cancer diag-nosis establishing novel biomarkers (melanocyte shape, NADPH, melanin concentration, Hb/HbO2 as well as lipid, water and DNA/RNA concentration)\tEnable exceptional commercial opportunities for SMEs\tProvide state-of-the-art academic training

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores